Evidence map›Paper›PMID 40135596›Full record

ArticleeLife2025

Induction of hepatitis B core protein aggregation targeting an unconventional binding site.

Vladimir Khayenko, Cihan Makbul, Clemens Schulte, Naomi Hemmelmann, Sonja Kachler, Bettina Böttcher, Hans Michael Maric

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vladimir Khayenko *Rudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.
Cihan Makbul *Rudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.
Clemens SchulteRudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.
Naomi HemmelmannRudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.
Sonja KachlerRudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.
Bettina BöttcherRudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0002-7962-4849
Hans Michael MaricRudolf Virchow Center, Center for Integrative and Translational Bioimaging; University of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0002-2719-4752

Funding

Deutsche Forschungsgemeinschaft 359471283Deutsche Forschungsgemeinschaft 456578072Deutsche Forschungsgemeinschaft 525040890Deutsche Forschungsgemeinschaft BO1150/17-1Deutsche Forschungsgemeinschaft DFG MA6957/1-1
6 · The paper itself

Abstract

The hepatitis B virus (HBV) infection is a major global health problem, with chronic infection leading to liver complications and high death toll. Current treatments, such as nucleos(t)ide analogs and interferon-α, effectively suppress viral replication but rarely cure the infection. To address this, new antivirals targeting different components of the HBV molecular machinery are being developed. Here we investigated the hepatitis B core protein (HBc) that forms the viral capsids and plays a vital role in the HBV life cycle. We explored two distinct binding pockets on the HBV capsid: the central hydrophobic pocket of HBc-dimers and the pocket at the tips of capsid spikes. We synthesized a geranyl dimer that binds to the central pocket with micromolar affinity, and dimeric peptides that bind the spike-tip pocket with sub-micromolar affinity. Cryo-electron microscopy further confirmed the binding of peptide dimers to the capsid spike tips and their capsid-aggregating properties. Finally, we show that the peptide dimers induce HBc aggregation in vitro and in living cells. Our findings highlight two tractable sites within the HBV capsid and provide an alternative strategy to affect HBV capsids.

Indexed as

Hepatitis B Core AntigensHepatitis B virusProtein AggregatesViral Core ProteinsAntiviral AgentsBinding SitesCapsidCryoelectron MicroscopyHumansPeptidesProtein BindingProtein MultimerizationAntiviral AgentsHepatitis B Core AntigensPeptidesProtein AggregatesViral Core ProteinsbiochemistryCAMscapsid assembly modulatorschemical biologycryo-electron microscopyCryo-EMHBchepatitis B core proteinhepatitis B virusnonepeptide

Identifiers

PMID40135596
PMCPMC11942178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.